The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Direct to Phase II SBIR Entitled “Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses”
Doylestown, PA. December 24, 2014- FCCDC is pleased to announce that it was been awarded a Direct to Phase II SBIR entitled “Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses” (R44AI115759-01), working in collaboration with Prof. Robert Ricciardi of the University of Pennsylvania.